Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Share Issue

AbCellera Reports Q1 2022 Business Results


AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

"We entered 2022 with strong momentum that we leveraged to start new drug discovery programs and demonstrate the power of our platform by discovering a panel of CD3 antibodies for use in precision cancer treatments," said Carl Hansen, Ph.D., CEO and President of AbCellera. "With our strong cash position and book of business, we also continued pursuing deal structures that allow us to capture more downstream value and expanded an existing partnership to include the option to co-develop therapeutic programs."

Q1 2022 Business Summary

Key Business Metrics

Cumulative Metrics

 

March 31, 2021

 

 

March 31, 2022

 

 

Change %

 

Number of discovery partners

 

 

29

 

 

 

36

 

 

 

24

%

Programs under contract

 

 

119

 

 

 

158

 

 

 

33

%

Program starts

 

 

54

 

 

 

84

 

 

 

56

%

Molecules in the clinic

 

 

1

 

 

 

6

 

 

 

500

%

AbCellera added two discovery programs in Q1 to reach a cumulative total of 158 discovery programs as of March 31, 2022 (up from 119 on March 31, 2021), that are either completed, in progress, or under contract with 36 different partners (up from 29 on March 31, 2021). AbCellera started discovery on an additional six programs in Q1 to reach a cumulative total of 84 program starts (up from 54 on March 31, 2021). AbCellera's partners advanced one additional molecule into the clinic in Q1 2022, bringing the cumulative total to six.

Discussion of Q1 2022 Financial Results

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Income and

Comprehensive Income

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)

(Unaudited)

 

 

Three months ended March 31,

 

 

 

2021

 

 

2022

 

Revenue:

 

 

 

 

 

 

 

 

Research fees

 

$

3,986

 

 

$

9,333

 

Licensing revenue

 

 

20,259

 

 

 

231

 

Milestone payments

 

 

7,000

 

 

 

-

 

Royalty revenue

 

 

171,496

 

 

 

307,017

 

Total revenue

 

 

202,741

 

 

 

316,581

 

Operating expenses:

 

 

 

 

 

 

 

 

Royalty fees

 

 

20,010

 

 

 

44,637

 

Research and development(1)

 

 

12,352

 

 

 

26,366

 

Sales and marketing(1)

 

 

2,578

 

 

 

2,370

 

General and administrative(1)

 

 

6,422

 

 

 

14,268

 

Depreciation and amortization

 

 

3,305

 

 

 

3,990

 

Total operating expenses

 

 

44,667

 

 

 

91,631

 

Income from operations

 

 

158,074

 

 

 

224,950

 

Other (income)

 

 

 

 

 

 

 

 

Other income

 

 

(265

)

 

 

(665

)

Grants and incentives

 

 

(3,148

)

 

 

(5,194

)

Total other (income)

 

 

(3,413

)

 

 

(5,859

)

Net earnings before income tax

 

 

161,487

 

 

 

230,809

 

Income tax expense

 

 

44,266

 

 

 

62,236

 

Net earnings

 

$

117,221

 

 

$

168,573

 

Foreign currency translation adjustment

 

 

-

 

 

 

507

 

Comprehensive income

 

$

117,221

 

 

$

169,080

 

 

 

 

 

 

 

 

 

 

Net earnings per share attributable to common shareholders

 

 

 

 

 

 

 

 

Basic

 

$

0.43

 

 

$

0.59

 

Diluted

 

$

0.37

 

 

$

0.54

 

Weighted-average common shares outstanding

 

 

 

 

 

 

 

 

Basic

 

 

269,697,212

 

 

 

283,895,020

 

Diluted

 

 

320,282,747

 

 

 

311,482,017

 

1 Exclusive of depreciation and amortization

 

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheet

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

 

 

December 31, 2021

 

 

March 31, 2022

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

476,142

 

 

$

545,718

 

Marketable securities

 

 

246,835

 

 

 

240,335

 

Total cash, cash equivalents, and marketable securities

 

 

722,977

 

 

 

786,053

 

Accounts and accrued receivable

 

 

160,576

 

 

 

334,403

 

Restricted cash

 

 

25,000

 

 

 

25,000

 

Other current assets

 

 

21,247

 

 

 

28,922

 

Total current assets

 

 

929,800

 

 

 

1,174,378

 

Long-term assets:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

111,616

 

 

 

122,049

 

Intangible assets, net

 

 

148,392

 

 

 

145,785

 

Goodwill

 

 

47,806

 

 

 

47,806

 

Investments in and loans to equity accounted investees

 

 

50,313

 

 

 

58,882

 

Other long-term assets

 

 

30,642

 

 

 

43,389

 

Total long-term assets

 

 

388,769

 

 

 

417,911

 

Total assets

 

$

1,318,569

 

 

$

1,592,289

 

Liabilities and shareholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other liabilities

 

$

32,017

 

 

$

25,717

 

Current portion of contingent consideration payable

 

 

22,934

 

 

 

27,499

 

Income taxes payable

 

 

35,683

 

 

 

105,648

 

Accrued royalties payable

 

 

22,506

 

 

 

45,364

 

Deferred revenue

 

 

7,536

 

 

 

9,190

 

Total current liabilities

 

 

120,676

 

 

 

213,418

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Operating lease liability

 

 

36,413

 

 

 

36,356

 

Deferred revenue and grant funding

 

 

60,758

 

 

 

64,151

 

Contingent consideration payable

 

 

35,886

 

 

 

30,623

 

Deferred tax liability

 

 

37,370

 

 

 

36,804

 

Other long-term liabilities

 

 

1,733

 

 

 

3,430

 

Total long-term liabilities

 

 

172,160

 

 

 

171,364

 

Total liabilities

 

 

292,836

 

 

 

384,782

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common shares: no par value, unlimited authorized shares at December 31, 2021 and March 31, 2022: 283,257,104 and 284,521,181 shares issued and outstanding at December 31, 2021 and March 31, 2022, respectively

 

 

722,430

 

 

 

725,755

 

Additional paid-in capital

 

 

35,357

 

 

 

44,726

 

Accumulated other comprehensive income

 

 

280

 

 

 

787

 

Accumulated earnings

 

 

267,666

 

 

 

436,239

 

Total shareholders' equity

 

 

1,025,733

 

 

 

1,207,507

 

Total liabilities and shareholders' equity

 

$

1,318,569

 

 

$

1,592,289

 

 

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars)

(Unaudited)

 

 

Three months ended March 31,

 

 

 

2021

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

117,221

 

 

$

168,573

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Depreciation of property and equipment

 

 

840

 

 

 

1,391

 

Amortization of intangible assets

 

 

2,465

 

 

 

2,606

 

Amortization of operating lease right-of-use assets

 

 

661

 

 

 

976

 

Stock-based compensation

 

 

5,427

 

 

 

12,291

 

Other

 

 

432

 

 

 

(592

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and accrued research fees receivable

 

 

(30,073

)

 

 

(8,751

)

Accrued royalties receivable

 

 

26,861

 

 

 

(167,914

)

Income taxes payable

 

 

(6,123

)

 

 

69,965

 

Accounts payable and accrued liabilities

 

 

(5,194

)

 

 

751

 

Deferred revenue

 

 

6,086

 

 

 

941

 

Accrued royalties payable

 

 

(7,134

)

 

 

22,857

 

Deferred grant revenue

 

 

2,468

 

 

 

4,682

 

Other assets

 

 

(4,392

)

 

 

(7,557

)

Net cash provided by operating activities

 

 

109,545

 

 

 

100,219

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(3,644

)

 

 

(14,495

)

Purchase of marketable securities

 

 

-

 

 

 

(51,774

)

Proceeds from marketable securities

 

 

-

 

 

 

57,294

 

Receipt of grant funding

 

 

-

 

 

 

2,596

 

Long-term investments and other assets

 

 

-

 

 

 

(11,657

)

Investment in and loans to equity accounted investees

 

 

(12,195

)

 

 

(8,335

)

Net cash used in investing activities

 

 

(15,839

)

 

 

(26,371

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Repayment of long-term debt and contingent consideration

 

 

(1,716

)

 

 

(72

)

Proceeds from long-term debt and issuance of common shares pursuant to exercise of stock options

 

 

173

 

 

 

1,941

 

Payment of liability for in-licensing agreement

 

 

-

 

 

 

(5,000

)

Net cash provided by (used in) financing activities

 

 

(1,543

)

 

 

(3,131

)

Effect of exchange rate changes on cash and cash equivalents

 

 

(484

)

 

 

(204

)

Increase in cash and cash equivalents

 

 

91,679

 

 

 

70,513

 

Cash and cash equivalents and restricted cash, beginning of period

 

 

594,116

 

 

 

501,142

 

Cash and cash equivalents and restricted cash, end of period

 

$

685,795

 

 

$

571,655

 

Restricted cash included in other long-term assets

 

 

-

 

 

 

(937

)

Total cash, cash equivalents and restricted cash shown in the statement of cash flows

 

$

685,795

 

 

$

570,718

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

Property plant and equipment in accounts payable

 

 

423

 

 

 

2,353

 

Right-of-use assets obtained in exchange for operating lease obligation

 

 

14,188

 

 

 

658

 

Source: AbCellera Biologics Inc.


These press releases may also interest you

2 jui 2022
The value of trade between the Hong Kong Special Administrative Region (HKSAR) and the Chinese mainland has surged more than sixfold from $50.77 billion to $360.33 billion, an average annual increase of 8.5 percent since the Hong Kong's return to the...

2 jui 2022
Premier Tech Home Security, a leader in providing security systems to homes in businesses in Middle Tennessee, is proud to announce the launch of their new website. Though the company offers their services across a wide geographic area, customers can...

2 jui 2022
Peng Liyuan, wife of Chinese President Xi Jinping, on Thursday visited the Xiqu Center in Hong Kong's West Kowloon Cultural District, a venue for the art of Chinese traditional theater.  She watched rehearsals of Cantonese opera performances and a...

2 jui 2022
Milloret LTD, a prestigious UK-registered European SEO Agency operating from the UK, and Spain announced today its mission to offer international SEO services to help grow clients' businesses. Milloret LTD  specializes in helping websites perform...

2 jui 2022
DesignMap, the industry-leading digital product design consultancy, is undertaking a strategic multiyear growth plan. The company, which has been providing strategic design services for leading Silicon Valley tech companies since 2006, not only...

2 jui 2022
In the Hype Cycle for Privacy, 2021, Gartner recognized Prime Factors among Sample Vendors in Privacy, a space that is a top priority for security and risk management leaders managing technology, information and resilience risk. For Format-Preserving...



News published on 10 may 2022 at 16:10 and distributed by: